Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

Lavanya Palavalli Parsons, MD
Published: Monday, Mar 26, 2018


Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

PARP belongs to a large family, but the PARP inhibitors that are currently approved only target a select few PARPs, Parsons notes. Her research focused on exploring the other PARPs and if they had a relationship to ovarian cancer.

Parsons found that PARP 7 was amplified in many patients with ovarian cancer, which caused them to have an overall survival benefit.  

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

PARP belongs to a large family, but the PARP inhibitors that are currently approved only target a select few PARPs, Parsons notes. Her research focused on exploring the other PARPs and if they had a relationship to ovarian cancer.

Parsons found that PARP 7 was amplified in many patients with ovarian cancer, which caused them to have an overall survival benefit.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Publication Bottom Border
Border Publication
x